Cyclic sulphone MMP inhibitors

Abstract

Matrix metalloproteinases (MMP) inhibitors have therapeutic potential in a variety of human diseases such as cancer, arthritis and multiple sclerosis. Over the last decade a large number of pharmaceutical companies have had active programmes in the area resulting in several orally bioavailable MMP inhibitors advancing into clinical trials. This patent claims a structurally relatively unique series of MMP inhibitors based on a novel cyclic sulphone scaffold. Compounds within this application have promising in vitro profiles, with nM potency against MMP-13, however since there is no in vivo efficacy or pharmacokinetic data as of yet, it is not possible at this time to ascertain if this series will offer any advantage over the current series of inhibitors.

• arthritis
• cancer
• hydroxamates
• MMP